Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica

Email

Notify me about related content and special offers.

Yes No

If you opt in above, we use this information to send related content, discounts, and other special offers.